CD274 and neoplasm: Remarkably, treatment with AP-diABZI completely eliminated observable EMT6 tumors, resulting in a 100% complete response (CR) rate (10/10 mice) whereas treatment with nAlb-diABZI, while still very effective, yielded a 30% CR rate (3/10 mice); nPD-L1-diABZI only modestly inhibited tumor growth, though to slightly greater extent than the conventional anti-PD-L1 IgG ICB, which conferred only minimal activity in this model.